IP Library Granted Patent US 9,217,026
Granted Patent B2
US 9,217,026 · App. 11/983,888 · Granted Dec 22, 2015

Method of inactivating a glucocorticoid receptor gene in an isolated cell

Inventors: Andreas Reik (Vallejo, CA); Michael Jensen (Sierra Madre, CA); Michael C. Holmes (Oakland, CA); Philip D. Gregory (Orinda, CA); Dale Ando (Walnut Creek, CA)
Assignee: Sangamo BioSciences, Inc.
C07K14/721C12N15/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,217,026
App. No.
11/983,888
Granted
Dec 22, 2015
Kind
B2
Abstract

Disclosed herein are methods and compositions for inactivation of the human glucocorticoid receptor (GR) gene by targeted cleavage of genomic DNA encoding the GR. Such methods and compositions are useful, for example, in therapeutic applications which require retention of immune function during glucocorticoid treatment.

Claims (31)

1. A method of inactivating a glucocorticoid receptor (GR) gene in an isolated cell, the method comprising:

A)(i) expressing a first fusion protein in an isolated cell, wherein the first fusion protein comprises:

a) a cleavage half-domain; and

b) a zinc finger DNA-binding domain that recognizes the nucleic acid sequence of SEQ ID NO: 4, wherein the zinc finger DNA-binding domain comprises the following recognition helices in the following order:

TSRALTA (SEQ ID NO: 23);

DRANLSR (SEQ ID NO: 17);

RSDNLSE (SEQ ID NO: 24); and

QNANRKT (SEQ ID NO: 25); and

(ii) expressing a second fusion protein in the isolated cell, wherein the second fusion protein comprises:

a) a cleavage half-domain; and

b) a zinc finger DNA-binding domain that recognizes the nucleic acid sequence of SEQ ID NO: 5, wherein the zinc finger DNA-binding domain comprises the following recognition helices in the following order:

RSDVLSE (SEQ ID NO: 14);

RSANLTR (SEQ ID NO: 27);

RSDNLST (SEQ ID NO: 28);

HSHARIK (SEQ ID NO: 29),

such that the first and second fusion proteins catalyze a double stranded break and inactivate the GR gene; or

B) i) expressing a first fusion protein in an isolated cell, wherein the first fusion protein comprises:

a) a cleavage half-domain; and

b) a first zinc finger DNA-binding domain that recognizes the nucleic acid sequence of SEQ ID NO: 4, wherein the zinc finger DNA-binding domain comprises the following recognition helices in the following order:

TSRALTA (SEQ ID NO: 23);

DRANLSR (SEQ ID NO: 17);

RSDNLSE (SEQ ID NO: 24); and

ERANRNS (SEQ ID NO: 26); and

(ii) expressing a second fusion protein in the isolated cell, wherein the second fusion protein comprises:

a) a cleavage half-domain; and

b) a zinc finger DNA-binding domain that recognizes the nucleic acid sequence of SEQ ID NO: 5, wherein the zinc finger DNA-binding domain comprises the following recognition helices in the following order:

DGWNRDC (SEQ ID NO: 32) or DSWNLQV (SEQ ID NO: 33);

RSANLTR (SEQ ID NO: 27);

TSGNLTR (SEQ ID NO: 30);

TSGSLTR (SEQ ID NO: 31),

such that the first and second fusion proteins catalyze a double stranded break and inactivate the GR gene.

Assignments (3)
CHANGE OF NAME Recorded Oct 9, 2020
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 054039/0995 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2008
From: JENSEN, MICHAEL
To: CITY OF HOPE
Reel/Frame 020724/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 24, 2008
From: REIK, ANDREAS; HOLMES, MICHAEL C.; GREGORY, PHILIP D.; ANDO, DALE
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 020724/0687 →
Continuity (4)
Provisional Application 60859025 · Nov 13, 2006
Provisional Application 60859417 · Nov 15, 2006
Provisional Application 60967820 · Sep 7, 2007
Related Publication 20080188000A1 · Aug 7, 2008